Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 07, 2023 12:16 ET | Source: Lixte Biotechnology Holdings, Inc.

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

--THE STUDY ESTABLISHES A NOVEL CONCEPT OF “TUMOR SUPPRESSIVE DRUG RESISTANCE” --THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN KILLING...
August 18, 2020 09:35 ET | Source: Lixte Biotechnology Holdings, Inc.

The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome

EAST SETAUKET, NY, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced an agreement with the Foundation for Angelman Syndrome Therapeutics (FAST) to...
November 05, 2018 13:00 ET | Source: Lixte Biotechnology Holdings, Inc.

FDA Approves Lixte Biotechnology’s IND to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center

EAST SETAUKET, NY, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced that the FDA approved its IND to conduct a Phase 1b/2 trial of the safety and...